Opioid Policy Research Collaborative, Institute for Behavioral Health, The Heller School for Social Policy and Management, Brandeis University, Waltham, Massachusetts (Dr Green, Mss Olson and Michelson, and Mr Jarczyk); Department of Emergency Medicine (Drs Green and Wightman) and Department of Internal Medicine (Dr del Pozo), Warren Alpert Medical School of Brown University, Rhode Island Hospital, Providence, Rhode Island; The Miriam Hospital, Providence, Rhode Island (Dr del Pozo); Centers for Disease Control and Prevention Foundation, Boston, Massachusetts (Ms Consigli); Bureau of Substance Addiction Services, Massachusetts Department of Public Health, Boston, Massachusetts (Mss Ruiz and Reilly); and Erowid Center's DrugsData, Grass Valley, California (Mx E. Erowid, Mx F. Erowid, and Ms Thyssen).
J Public Health Manag Pract. 2022;28(Suppl 6):S347-S354. doi: 10.1097/PHH.0000000000001581.
The illicit drug supply is rapidly evolving. Equally important to gathering drug supply data for monitoring is timely sharing of information with people who use drugs, the providers who care for them, law enforcement partners, and public health stakeholders so that efforts to avoid harmful substances, take preventive actions, and better target interventions can occur.
The Massachusetts Drug Supply Data Stream (MADDS) is the country's first statewide community drug checking program. Founded on public health-public safety partnerships, MADDS collects remnant drug packaging and paraphernalia with residue from people who use drugs and noncriminal samples from partnering police departments. MADDS tests samples using simultaneous immunoassay fentanyl test strips, Fourier-transform infrared spectrometry (FTIR), and off-site laboratory testing by gas chromatography-mass spectrometry (GC/MS). Results are accessible to community programs and municipalities, while trend analyses inform public health for cross-site alerts and informational bulletins.
MADDS was launched statewide in 2020 and rapidly expanded to a multisite program. Program staff approached communities and met with municipal police and community partners to secure written agreements to host drug checking. Community partners designed sample collection consistent with their pandemic era workflows. Consultations with stakeholders gathered feedback on design and deliverables.
The program tests sample donations on-site from community agencies and police departments, incorporates review by a medical toxicologist for health and safety concerns, crafts stakeholder-specific communications, and disseminates English, Spanish, and Portuguese language materials. For 2020, a total of 427 samples were tested, of which 47.1% were positive for fentanyl. By early 2021, MADDS detected shifts in cocaine purity, alerted communities of a new toxic fentanyl analogue and a synthetic cannabinoid contaminant, and confirmed the increase of xylazine (a veterinary sedative) in Massachusetts.
Community drug checking programs can be collaboratively designed with public health and public safety to generate critical health and safety information for people who use drugs and the communities where they live.
非法毒品供应正在迅速演变。除了收集毒品供应数据进行监测外,同样重要的是,及时与吸毒者、照顾他们的提供者、执法伙伴和公共卫生利益相关者分享信息,以便能够避免有害物质、采取预防措施,并更好地将干预措施针对目标。
马萨诸塞州毒品供应数据流 (MADDS) 是美国第一个全州范围的社区毒品检测计划。该项目建立在公共卫生-公共安全伙伴关系的基础上,从吸毒者和来自合作警察局的非犯罪样本中收集剩余的毒品包装和用具。MADDS 使用同时进行的免疫测定芬太尼测试条、傅里叶变换红外光谱 (FTIR) 和场外实验室气相色谱-质谱 (GC/MS) 测试样本。结果可供社区计划和市政府使用,而趋势分析则为跨站点警报和信息公告提供公共卫生信息。
MADDS 于 2020 年在全州范围内推出,并迅速扩展为多站点计划。项目工作人员与社区接触,并与市警察和社区伙伴会面,以确保获得托管毒品检测的书面协议。社区合作伙伴根据大流行时代的工作流程设计了样本收集工作。与利益相关者的磋商收集了对设计和交付成果的反馈意见。
该计划在现场测试来自社区机构和警察局的样本捐赠,由医学毒理学家审查健康和安全问题,制定特定于利益相关者的沟通方式,并传播英语、西班牙语和葡萄牙语材料。2020 年,共检测了 427 个样本,其中 47.1% 对芬太尼呈阳性。到 2021 年初,MADDS 检测到可卡因纯度的变化,提醒社区注意一种新的有毒芬太尼类似物和一种合成大麻素污染物,并证实了马萨诸塞州苯佐卡因(一种兽医镇静剂)的增加。
社区毒品检测计划可以与公共卫生和公共安全合作设计,为吸毒者及其居住的社区提供关键的健康和安全信息。